Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.

Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its stock even as the news also emerged that Takeda had pulled out of a Huntington's disease alliance with the biotech.

Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of patients with a genetic disorder that can lead to lung or liver disease. T

Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential life threatening and implicating the lungs and liver. As recently demonstrated in a Phase I and II concept trial,

Wave Life Sciences (WVE) shares soared 66% after the company announced positive proof-of-mechanism data from a study of WVE-006 in the treatment of AATD. Read more here.